Skip to content

Abstract 14482: Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists versus DPP-4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matched Real-World Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP1RA) and dipeptidyl peptidase-4 inhibitors (DPP4i) are commonly used second-line agents in type 2 diabetes mellitus (T2DM). This large-scale real-world analysis compared their effects on major clinical outcomes. Methods: Using the TriNetX Research network, we identified patients initiating GLP1RA and DPP4i with T2DM, aged ≥18 years, excluding type 1 diabetes. Propensity score matching (1:1) balanced the cohorts. Index date was the first prescription of the respective drug class. Outcomes were assessed from 1 day to 1,825 days (5 years) post-index using risk analysis, Kaplan-Meier survival, and number-of-instances methods, excluding patients with the outcome prior to the time window. Results: After matching, GLP1RA use was associated with substantially lower risk of several key outcomes compared to DPP4i. All-cause mortality was markedly reduced (5.6% vs 10.4%; risk ratio 0.536, 95% CI 0.526-0.545; HR 0.474, 95% CI 0.465-0.483; log-rank p<0.001), with 5-year survival of 90.83% vs 82.83%.Cardiovascular benefits included lower myocardial infarction (3.2% vs 3.6%; risk ratio 0.894; HR 0.793), cerebral infarction (3.0% vs 3.5%; risk ratio 0.872; HR 0.777), heart failure (survival HR 0.882), and cardiac arrest (0.8% vs 1.3%; risk ratio 0.609; HR 0.542). Renal outcomes showed lower acute kidney injury (8.5% vs 9.4%; risk ratio 0.911; HR 0.815) and chronic kidney disease (11.6% vs 12.2%; risk ratio 0.957; HR 0.851). Ophthalmic complications (6.4% vs 4.6%) and polyneuropathy (7.6% vs 5.3%) were higher with GLP1RA. Conclusions: In this large propensity score-matched real-world cohort of patients with T2DM, GLP1RA initiation was associated with substantially lower all-cause mortality, reduced cardiovascular events, and better renal outcomes compared to DPP4i over 5 years, supporting the preferential use of GLP1RA in appropriate patients.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.